Bolt Biotherapeutics, Inc. (BOLT)
After hours:
- GlobeNewswire
Bolt Biotherapeutics Announces Changes to its Board of Directors
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appointment of Dr. Dupont, Executive Partner at Sofinnova Investments, Dr. Jim Healy, M.D., Ph.D., also at Sof
- GlobeNewswire
Bolt Biotherapeutics to Participate in Upcoming September Conferences
REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in September: Morgan Stanley 22nd Annual Global Healthcare ConferenceFireside chat on Friday, Sept. 6, at 7:00 a.m. EDT (4:00 a.m. PDT)H.C. Wainwright 26th Annual Global Investment ConferenceCompany presentation available on
